APOE and Alzheimer disease: In individual MCI subjects with APOE ε4, a positive Aβ PET biomarker significantly discriminated MCI due to AD (SS = 100%, SP = 28.5%) in addition to individual APOE ε4 non-carriers (SS = 93.7%, SP = 50%), compared to negative biomarker.